Cardiogenic Shock

This page includes content on technologies to treat cardiogenic shock, including percutaneous ventricular assist devices (pVAD), intra-aortic balloon pumps (IABP) and extracorporeal membrane oxygenation (ECMO). This condition occurs when the heart can no longer pump enough oxygenated blood to the body. The most common cause of cardiogenic shock is damage to the heart from a severe heart attack. The standard of care for this condition for more than 20 years has a 50 percent survival rate, but improvements have recently been seen in studies using early pVAD intervention prior to percutaneous coronary intervention (PCI). For more information, visit the National Institute of Health (NIH) cardiogenic shock information page

The Abiomed Impella percutaneous heart pump was shown in the NCSI study to greatly improve survival of acute myocardial infarction with cardiogenic shock (AMICS), raising survival from 50 percent to 71 percent. Ambulance image from Getty Images.

The Abiomed Impella percutaneous heart pump was shown in the NCSI study to greatly improve survival of acute myocardial infarction with cardiogenic shock (AMICS), raising survival from 50 percent to 71 percent. Ambulance image from Getty Images.

Feature | Cardiogenic Shock | April 29, 2021 | By Dave Fornell, Editor
April 29, 2021 — The results of a large, national heart attack study show that patients with  cardiogenic shock...
Videos | Cardiogenic Shock | April 28, 2021
William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit,...
The Abiomed Breethe OXY-1 System has received U.S. FDA 510(k) clearance. 
Feature | ECMO Systems | October 26, 2020
October 26, 2020 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed for an all-in-...
Videos | Hemodynamic Support Devices | October 20, 2020
Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the...
Large Study in Japan Finds High Survival Rates With Impella Heart Pump
News | Cardiogenic Shock | August 03, 2020
August 3, 2020 — A three-year, investigator-led, prospective study of Japanese patients who received an Impella heart...
Videos | Cardiogenic Shock | July 15, 2020
Navin Kapur, M.D., FAHA, FACC, FSCAI, director, Acute Mechanical Circulatory Support Program and executive director of...
Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosai

Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosaic pattern with a bronchocentric distribution to the GGO (white arrow, d) involving both central and peripheral lung parenchyma with pleural effusions (black small arrow, d). image courtesy of Radiological Society of North America

Feature | Coronavirus (COVID-19) | June 30, 2020
In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association with prior exposure...
Russian interventional cardiologist Alexey Pankov in full personal protective equipment (PPE) for a cath lab procedure in Moscow during the COVID-19 era. Right, an image of the COVID-19 virus from the National Institutes of Health (NIH).

Russian interventional cardiologist Alexey Pankov in full personal protective equipment (PPE) for a cath lab procedure in Moscow during the COVID-19 era. Right, an image of the COVID-19 virus from the National Institutes of Health (NIH). Novel coronavirus has turned out to have a sizable amount of cardiovascular involvement.

Feature | Coronavirus (COVID-19) | June 05, 2020 | Dave Fornell, Editor
It was originally thought novel coronavirus (COVID-19, SARS-CoV-2) was primarily a respiratory disorder, but as larger...
Videos | Hemodynamic Support Devices | June 05, 2020
This is a quick animation demonstrating how the new 9 French Abiomed Impella ECP expands to approximately 18 French and...
Rash on the skin of a child who has COVID-19 related multi-system inflammatory syndrome (MIS-C). Image copyright Damien Bonnet, M.D., Ph.D., courtesy of the American Heart Association. Coronavirus is linked with this Kawasaki-like inflammatory disease in children.

Rash on the skin of a child who has COVID-19 related multi-system inflammatory syndrome (MIS-C). The image is from  Damien Bonnet, M.D., Ph.D., Necker Hospital-Université, Paris, who was involved in a Circulation study published on MIS-C May 14. Image copyright Damien Bonnet, courtesy of the American Heart Association.

Feature | Coronavirus (COVID-19) | May 20, 2020 | Dave Fornell, Editor
(UPDATE December 28, 2020 — Newer articles and video on MIS-C can be found in the related content section at the bottom...
Abiomed Adds ECMO Cardiopulmonary Support to its Portfolio with the purchase of Breethe. The Breethe ECMO system. Abiomed invested in Breethe in mid-2019. Breethe has applied for 510(k) clearance by the Food and Drug Administration (FDA).

The Breethe ECMO system. Abiomed invested in Breethe in mid-2019. Breethe has applied for 510(k) clearance by the Food and Drug Administration (FDA).

News | ECMO Systems | May 01, 2020
May 1, 2020 — Abiomed, maker of the Impella heart pump, has acquired Breethe, developer of a novel extracorporeal...
LivaNova Modifies its ECMO Indications Beyond Six Hours to Address COVID-19. The FDA expanded the use indications for ECMO systems April 6 so tthey can be used beyond six hours and for use in COVID-19 patients in need of circulatory and pulmonary support.

The FDA expanded the use indications for ECMO systems April 6 so the systems can be used beyond six hours and for use in COVID-19 patients in need of circulatory and pulmonary support. Image shows an ECMO team at work at Tufts Medical Center in Boston in December 2019. Photo by Dave Fornell

News | Coronavirus (COVID-19) | April 23, 2020
April 23, 2020 – LivaNova PLC said the U.S. Food and Drug Administration (FDA) is now permitting the company to expand...
Videos | Hemodynamic Support Devices | January 24, 2020
Navin Kapur, M.D., FAHA, FACC, FSCAI, director, Acute Mechanical Circulatory Support Program and executive director of...
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...